Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.98 HKD | +2.95% | +0.43% | +4.49% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.49% | 602M | |
+38.87% | 728B | |
+33.05% | 603B | |
-5.45% | 360B | |
+18.97% | 332B | |
+1.60% | 279B | |
+16.00% | 244B | |
+8.09% | 207B | |
-5.77% | 205B | |
+6.55% | 164B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug